Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 5/20 | 0.59 |
| ▸ | FGFR1 | P11362 | 16/20 | 0.51 |
| ▸ | KDR | P35968 | 3/20 | 0.51 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.49 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.49 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.49 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.49 |
| ▸ | FLT1 | P17948 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3540615 | 0.88 | FGFR1 (0.49) | ABL1FGFR1KDRPDGFRAFGFR2 | |
| SCHEMBL3544240 | 0.86 | FGFR1 (0.44) | ABL1FGFR1KDRPDGFRAFGFR2 | |
| SCHEMBL3540847 | 0.85 | FGFR1 (0.49) | ABL1FGFR1KDRFLT1 | |
| SCHEMBL3540476 | 0.83 | FGFR1 (0.46) | ABL1FGFR1KDRPDGFRAFGFR2 | |
| SCHEMBL3538553 | 0.83 | FGFR1 (0.46) | ABL1FGFR1KDRPDGFRAFGFR2 | |
| SCHEMBL3537444 | 0.83 | FGFR1 (0.56) | ABL1FGFR1KDRFLT1 | |
| SCHEMBL3607200 | 0.80 | ABL1 (0.66) | ABL1FGFR1KDRPDGFRAFGFR2 | |
| SCHEMBL3537860 | 0.80 | ABL1 (0.66) | ABL1FGFR1KDRPDGFRAFGFR2 | |
| SCHEMBL3537855 | 0.80 | ABL1 (0.66) | ABL1FGFR1KDRPDGFRAFGFR2 | |
| SCHEMBL3537166 | 0.78 | ABL1 (0.51) | ABL1FGFR1KDRPDGFRAFGFR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7642278-B2 | Nitrogen compounds such as 3-(5-morpholin-4-yl-1H-benz-imidazol-2-yl)-1H-indazole and/or isomers, used as immunology modulators, antidiabetic agents, antiogenesis inhibitors or for prophylaxis of Alzheimer's disease | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2010-01-05 | — | — | US | disclosed |
| US-7064215-B2 | Indazole benzimidazole compounds | CHIRON CORPORATION (US) | 2006-06-20 | — | — | US | disclosed |
| US-20060079564-A1 | Indazole benzimidazole compounds | CHIRON CORPORATION | 2006-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079564-A1 | Indazole benzimidazole compounds | ABL1, ABL2, ALK | ABL1 1/4885FGFR1 886/4885KDR 2852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.